# Pathalys Pharma Presents Positive Data from Pivotal Phase 3 Studies of Upacicalcet in Featured Oral Presentation at ASN Kidney Week 2026

- Source: PR Newswire
- Published: 2026-10-23T23:30:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/pathalys-pharma-presents-positive-data-from-pivotal-phase-3-studies-of-upacicalcet-in-featured-oral-presentation-at-asn-kidney-week-2026-302918517.html
- Canonical: https://groundlevelnews.com/story/pathalys-pharma-presents-positive-data-from-pivotal-phase-3-studies-of-4e7027/

~ In PATH-1 and PATH-2 upacicalcet met primary and key secondary endpoints of reducing parathyroid hormone (PTH) in patients with end-stage kidney disease and Secondary Hyperparathyroidism (SHPT) on hemodialysis ~ Upacicalcet also reduced FGF23 and markers of bone turnover in the trial...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire._